Clinical Trial Update: Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring osimertinib plus bevacizumab in untreated EGFR Exon21 L858R-mutated lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN